Skip to main content

Merck & Company Inc (MRK) Stock

Merck & Company Inc Stock Details, Movements and Public Alerts

Merck & Company (MRK): Managing the Keytruda Patent Cliff While Building a $70 Billion Pipeline

Rob Davis faces the defining challenge for any pharma CEO: replacing $31.7 billion in annual Keytruda revenue before patents expire in 2028-2029. The cancer immunotherapy became the best-selling drug in the world, but its impending loss of exclusivity hangs over Merck's stock like a shadow. Davis's response has been aggressive pipeline building and acquisition. Winrevair (pulmonary arterial hypertension) reached $1.4 billion in its first full year of sales and is projected to hit $3.9 billion by 2029. The company describes $70 billion in total commercial opportunities from 20+ growth drivers, more than double the consensus Keytruda peak. Merck is also cutting $3 billion in costs by 2027 and developing subcutaneous Keytruda formulations to extend patent protection. At $121 with a 3%+ dividend yield, the stock offers pharma stability but demands conviction that the pipeline can replace the franchise drug.

52-Week Range

$124.22 - $70.74

-6.84% from high · +63.58% from low

Avg Daily Volume

9,862,728

20-day average

100-day avg: 13,047,450

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

15.88

Near market average

Forward P/E

22.52

Earnings expected to decline

PEG Ratio

3.52

Potentially overvalued

Price to Book

5.43

EV/EBITDA

11.34

EPS (TTM)

$7.28

Price to Sales

4.40

Beta

0.26

Less volatile than market

Q:How is MRK valued relative to its earnings and growth?
Merck & Company Inc trades at a P/E ratio of 15.88, which is near the market average of approximately 20, suggesting the market views it as fairly valued relative to its earnings. Looking ahead, the forward P/E of 22.52 is higher than the current P/E, indicating analysts expect earnings to decline over the next year. The PEG ratio of 3.52 indicates a premium valuation even accounting for growth.
Q:What is MRK's risk profile compared to the market?
With a beta of 0.26, Merck & Company Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 5.43 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

28.10%

Operating Margin

32.80%

EBITDA

$29.11B

Return on Equity

36.90%

Return on Assets

12.00%

Revenue Growth (YoY)

5.00%

Earnings Growth (YoY)

-19.30%

Q:How profitable and efficient is MRK's business model?
Merck & Company Inc achieves a profit margin of 28.10%, meaning it retains $28.10 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 32.80% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 36.90% and ROA at 12.00%, the company generates strong returns on invested capital.
Q:What are MRK's recent growth trends?
Merck & Company Inc's revenue grew by 5.00% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings decreased by 19.30% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against DRUG MANUFACTURERS - GENERAL industry averages for proper context.

Dividend Information

Dividend Per Share

$3.24

Dividend Yield

2.80%

Ex-Dividend Date

Mar 16, 2026

Dividend Date

Apr 7, 2026

Q:What dividend income can investors expect from MRK?
Merck & Company Inc offers a dividend yield of 2.80%, paying $3.24 per share annually. This above-average yield of 2-4% provides meaningful income while still allowing the company to reinvest for growth. It compares favorably to the S&P 500 average and offers competitive returns versus bonds in the current rate environment. To receive the next dividend, shares must be purchased before the ex-dividend date of Mar 16, 2026.
Q:How reliable is MRK's dividend for long-term investors?
The dividend sustainability can be assessed through the payout ratio - Merck & Company Inc pays $3.24 per share in dividends against earnings of $7.28 per share, resulting in a payout ratio of 44.51%. This balanced payout between 30-60% suggests a sustainable dividend policy that allows both shareholder returns and business reinvestment. The dividend appears well-covered by earnings. The next dividend payment is scheduled for Apr 7, 2026.

Company Size & Market

Market Cap

$285.8B

Revenue (TTM)

$65.01B

Revenue/Share (TTM)

$25.98

Shares Outstanding

2.47B

Book Value/Share

$21.26

Asset Type

Common Stock

Q:What is MRK's market capitalization and position?
Merck & Company Inc has a market capitalization of $285.8B, classifying it as a mega-cap stock (over $200B). These are the largest, most established companies globally, typically offering stability and liquidity but with more modest growth potential. Mega-caps often pay dividends and weather economic downturns better than smaller companies. With 2.47B shares outstanding, the company's ownership is widely distributed. As a major player in the DRUG MANUFACTURERS - GENERAL industry, it competes with other firms in this sector.
Q:How does MRK's price compare to its book value?
Merck & Company Inc's book value per share is $21.26, while the current stock price is $115.72, resulting in a price-to-book (P/B) ratio of 5.44. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$127.78

10.42% upside potential

Analyst Recommendations

Strong Buy

4

Buy

15

Hold

11

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for MRK?
30 analysts cover MRK with 63% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $127.78 implies 10.4% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on MRK?
Current analyst recommendations:4 Strong Buy, 15 Buy, 11 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Mar 17, 2026, 02:17 AM

Technical Indicators

RSI (14-day)

46.81

Neutral

50-Day Moving Average

$114.28

1.26% above MA-50

200-Day Moving Average

$92.36

25.29% above MA-200

MACD Line

0.03

MACD Signal

0.97

MACD Histogram

-0.94

Bearish

Q:What does MRK's RSI value tell investors?
The RSI (Relative Strength Index) for MRK is currently 46.81, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being above the 50-day moving average, this shows mixed signals requiring careful analysis.
Q:How should traders interpret MRK's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.03 below the signal line at 0.97, with histogram at -0.94. This bearish crossover indicates downward pressure. The 50-day MA ($114.28) is above the 200-day MA ($92.36), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Mar 17, 2026, 12:43 AM

Active Alerts

Alert Condition
P/E Ratio falls below
Threshold
11 x
Created
Dec 3, 2025, 09:36 PM

Merck & Company (MRK) Stock Analysis 2025: Complete Investment Guide

The Keytruda Question

Keytruda (pembrolizumab) generated $31.7 billion in 2025 revenue, accounting for nearly half of Merck's total sales. The PD-1 checkpoint inhibitor is approved across 40+ tumor types and has become the backbone of cancer treatment globally. The compound patent expires in December 2028, with additional patents potentially extending protection to late 2029. CEO Rob Davis describes this timeline as a hill rather than a cliff, arguing that subcutaneous formulations, combination therapies, and new indications can slow the revenue decline.

The market is less optimistic. Merck's stock has underperformed the pharma sector as investors question whether the pipeline can realistically replace $30+ billion in peak Keytruda revenue. Davis's $70 billion opportunity framework across oncology ($25B), cardiometabolic ($20B), and infectious disease ($15B) is ambitious. The execution burden falls on 20+ growth drivers that must collectively deliver, since no single asset can replace Keytruda alone.

Business Model and Competitive Position

Merck operates across pharmaceutical and animal health segments. The pharmaceutical business spans oncology (Keytruda, Welireg, Lynparza), vaccines (Gardasil HPV, Vaxneuvance pneumococcal), cardiometabolic (Winrevair, Januvia/Janumet), and hospital acute care. The animal health segment (Merck Animal Health) is the second-largest in the world, providing diversification outside human pharma.

The competitive moat in oncology runs deep. Keytruda is entrenched across dozens of cancer treatment protocols as both monotherapy and in combination with other drugs. Even after patent expiration, biosimilar PD-1 antibodies will need to demonstrate similar efficacy across all approved indications, which takes years. The subcutaneous formulation under development could provide additional differentiation and convenience. Merck's partnerships with Moderna (cancer vaccines) and Daiichi Sankyo (ADCs) add next-generation oncology assets to the portfolio.

Financial Performance

  • •FY2025 Revenue: $65B (+1% YoY); Keytruda $31.7B (+7%), Winrevair $1.4B (first full year)
  • •FY2026 Guidance: Revenue $65.5B-$67B; adjusted EPS $5.00-$5.15
  • •Cost Savings: $3B in cuts by end of 2027 to protect margins through patent transition
  • •Dividend: 3%+ yield; decades of consecutive dividend increases
  • •Gardasil: HPV vaccine facing near-term headwinds in China but long-term global opportunity intact
  • •Animal Health: Steady mid-single-digit growth providing diversification from pharma volatility

Growth Catalysts

  • •Winrevair Expansion: PAH treatment ramping globally with $3.9B projected sales by 2029; potential in additional cardiovascular indications
  • •Cancer Vaccine with Moderna: mRNA-4157 personalized cancer vaccine in Phase 3 across melanoma, NSCLC, bladder, and renal cancers
  • •ADC Partnership with Daiichi Sankyo: Three antibody-drug conjugate candidates targeting multiple solid tumors
  • •Subcutaneous Keytruda: SC formulation extending Keytruda's competitive position post-patent with convenience and compliance advantages
  • •Cardiometabolic Pipeline: $20B opportunity including Winrevair and next-generation metabolic disease programs

Risks and Challenges

  • •Keytruda Patent Cliff: $31.7B in annual revenue at risk starting 2028-2029; biosimilar competition could erode sales faster than management projects
  • •Pipeline Execution: Replacing Keytruda requires 20+ programs to succeed; pipeline attrition is inherent in drug development
  • •Gardasil China Weakness: HPV vaccine facing inventory challenges and competitive pressure in China, a key growth market
  • •Generic Competition: Multiple drugs losing patent protection in 2026-2027 creating near-term revenue headwinds
  • •Acquisition Risk: Large deals needed to fill the Keytruda gap carry integration risk and premium pricing in the current pharma M&A market

Competitive Landscape

In oncology, Bristol-Myers Squibb's Opdivo is the closest PD-1 competitor, while Roche and AstraZeneca offer competing immunotherapy platforms. In the PD-1 biosimilar race, multiple companies (Samsung Bioepis, Sandoz, Coherus) are developing Keytruda biosimilars for 2028+ launch. In PAH, Winrevair competes with established therapies from United Therapeutics and Johnson & Johnson.

Among diversified pharma peers, Merck's concentration risk is higher than average. Keytruda accounts for nearly 50% of total revenue, compared to more diversified portfolios at Pfizer, Johnson & Johnson, and AbbVie. This concentration makes Merck more vulnerable to the patent cliff but also means the pipeline upside is more impactful on a relative basis.

Who Is This Stock Suitable For?

Perfect For

  • ✓Income investors seeking a 3%+ dividend yield from a pharma blue chip with decades of dividend growth
  • ✓Long-term holders who believe the $70B pipeline opportunity can offset Keytruda's decline
  • ✓Diversified portfolio builders wanting large-cap healthcare exposure
  • ✓Contrarian buyers willing to own a stock the market is discounting for a known risk

Less Suitable For

  • ✗Growth investors needing revenue acceleration (2026 growth will be modest at best)
  • ✗Risk-averse investors uncomfortable with the $31.7B Keytruda cliff concentrated in 2028-2029
  • ✗Momentum traders (stock likely range-bound until pipeline clarity emerges)
  • ✗Investors who prefer diversified pharma companies with lower single-drug concentration

Investment Thesis

Merck at $121 offers a 3%+ dividend yield and exposure to the world's most successful cancer drug franchise, plus a deep pipeline that management values at $70 billion in commercial opportunity. Rob Davis has been transparent about the Keytruda transition timeline and is investing aggressively in partnerships (Moderna, Daiichi Sankyo) and internal R&D to build the replacement portfolio. The $3 billion cost reduction program provides margin protection.

The critical variable is pipeline conversion. Twenty-plus growth drivers need to advance through clinical trials, receive regulatory approval, and achieve commercial launch over the next five years. Some will fail. The question is whether enough succeed to collectively replace Keytruda's contribution. At current prices, the market is pricing in significant erosion. Investors buying here are betting that Davis's hill-not-cliff framework proves correct and that the pipeline delivers enough wins to sustain growth beyond 2029.

Conclusion

Merck is a solid income holding with pipeline optionality for investors comfortable with the Keytruda transition risk. The stock is reasonably valued at current levels, offering a balance of dividend income and long-term growth potential. Position sizing should reflect the concentration risk around the 2028-2029 patent cliff.
Bull Case
$160 (32% upside) - Pipeline delivers multiple blockbusters, Keytruda erosion slower than feared, Winrevair exceeds $4B
Base Case
$130 (7% upside) - Gradual pipeline progress, Keytruda decline managed, dividend grows, modest re-rating
Bear Case
$85 (30% downside) - Pipeline attrition accelerates, Keytruda biosimilars capture share faster than expected, Gardasil struggles continue

Stay Ahead of the Market with Merck & Company Inc Alerts

Set up price alerts for Merck & Company Inc and get notified instantly when the price hits your target. Never miss an important price movement again.